PMGC Holdings (ELAB) Total Debt (2023 - 2026)

PMGC Holdings (ELAB) posted Total Debt of $5.3 million for Q1 2026, up 297.21% sequentially from $1.3 million in Q4 2025.

PMGC Holdings (ELAB) Total Debt (2023 - 2026) Analysis & Trends

PMGC Holdings has reported Total Debt for 4 years, with the latest figure at $5.3 million in Q1 2026.

Quarterly Total Debt changed N/A year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (changed N/A YoY) and the FY2025 annual result came in at $1.3 million, changed N/A from the prior year.
Total Debt rose to $5.3 million in Q1 2026 per ELAB's latest filing, from $1.3 million in the prior quarter.
Over five years, Total Debt peaked at $5.3 million in Q1 2026 and troughed at $77127.0 in Q4 2023.
A 4-year average of $1.8 million and a median of $1.2 million in 2024 frame the typical range for Total Debt.
The widest YoY moves for Total Debt: up 161.87% in 2025, down 161.87% in 2025.
Over 4 years, Total Debt stood at $77127.0 in 2023, then soared by 1481.43% to $1.2 million in 2024, then grew by 9.82% to $1.3 million in 2025, then soared by 297.21% to $5.3 million in 2026.
According to Business Quant data, Total Debt over the past three periods registered $5.3 million, $1.3 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	9.34 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	770.36 Mn
10	PMGC Holdings	3.01 Mn	-15.78 Mn	385,691.00	9.08 Mn

Download Data